Nowadays, we are living longer and better in Switzerland because the population is benefiting from innovative medicinal products and has access to high-quality healthcare. Yet there is a need for action and improvement in a number of areas, and there are new challenges that are in urgent need of solutions. These include, for example, promotion of a world-leading ecosystem for health data, flexible reimbursement models for innovations and more intensive cooperation with the authorities.
3 questions to Thorsten Hein - Member of theInterpharma Board and Country Division Head Pharmaceuticals Bayer Switzerland
3 questions to Max Pahlow - Member Interpharma Board and Managing Director, Janssen Switzerland
3 questions Pierre Morneau (General Manager Takeda Schweiz, Takeda Pharma AG) - Vice Chair Innovation Hub Committee
Quality before costs, less willingness to do without
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2022
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives